Global Primary Biliary Cholangitis Therapeutics Market Report and Forecast 2024-2032

Global Primary Biliary Cholangitis Therapeutics Market Outlook

The global primary biliary cholangitis therapeutics market is expected to grow at a CAGR of about 10.5% in the forecast period of 2024-2032. One of the key drivers for the industry growth is the increasing awareness campaigns to mitigate more complications in the primary biliary cholangitis indicator.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Segmentation

Primary biliary cholangitis refers to a rare chronic disease of the liver, formerly referred to as primary biliary cirrhosis, mainly characterized by the degradation of the biliary ducts, which contain bile acid from the skin. Even though the root cause of the disease has still not been established, worldwide work has shown that the disorder is autoimmune in nature. The progression of this disease contributes to the destructive deposition of bile acid, which causes serious liver damage. The disease mainly affects middle-aged women. The lack of a conclusive treatment for primary biliary cholangitis (PBC) offers an incredibly lucrative business opportunity.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

The industry can be broadly categorised based on its type into:

• OCALIVA
• Ursodiol
• Others

The EMR report looks into the regional markets of primary biliary cholangitis therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

The increasing awareness campaigns aimed at reducing any more complications in the primary indication of cholangitis are among the main drivers of the industry growth. The asymptomatic nature of the condition, in most cases, leads to a delay in diagnosis. Moreover, the majority of the population is not aware of the signs of the disease. Many sellers took advantage of this and began to organize awareness campaigns. Many non-profit organizations also run prevention campaigns and fund research into new disease therapies. Such factors will expand the sales of primary biliary cholangitis therapies and enable the market to grow.

Regenerative therapy study gains traction as an experimental liver transplant phase triggers a problem for patients following surgery. However, owing to the chronic nature of the disease, there is currently no treatment for the symptom other than a liver transplant. It allows researchers to perform a stem cell transplantation test that can replace those cells destroyed in the bile duct. This current research should have a positive effect on the overall growth of the market.

Competitive Landscape

The report presents a detailed analysis of the following key players in the global primary biliary cholangitis therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Intercept Pharmaceuticals, Inc.
• Novartis AG
• Glenmark Pharmaceuticals Ltd.
• Abbott Laboratories
• AbbVie Inc.
• Others

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report